Patients Coming Off Anti-Obesity Medications Put On Pounds at a Quadrupled Rate Than People Using Diet and Exercise

New research suggests that individuals who discontinue popular slimming jabs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt conventional diet and exercise regimens.

Findings released in a leading medical journal shows that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month upon discontinuation.

"Users buying these treatments must be aware of the risk of rapid weight regain when the therapy concludes," cautioned lead investigator Dr. Susan Jebb.

That rate of recovery means a return to original mass in about one and a half years.

Weighing Approaches

The analysis, which examined 37 of studies involving thousands of participants, contrasted the outcomes of these new drugs with older methods.

Scientists point out that people who shed pounds through lifestyle changes alone usually see a less rapid creep back—approximately 0.1 kg a month—once they finish.

The Reason for the Fast Regain

Experts propose the mode of action of the jabs is key to understanding the heightened rebound.

The injections mimic a body's own chemical called GLP-1, which moderates feelings of fullness.

"Long-term administration of GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.

"Withdrawal of this hormone supplement results in appetite is uncontrolled, making overeating a significant risk."

A Lifelong Condition?

Medical guidelines suggest the jabs for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.

Professionals say that, given the likelihood of weight regain, the therapy should be considered ongoing.

This perspective is supported by drug manufacturers, who say that the findings "highlight the chronic nature of obesity," akin to managing diseases like high blood pressure.

User Experiences

Individuals who have come off the jabs report a intense return of appetite.

"It was like something that goes on and you become extremely hungry," described one woman.

This challenge is worsened if individuals have not established sustainable dietary or behavioural modifications during therapy.

Significant Interest

Survey data suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand continuing to grow.

• Use is more common among females compared to males.
• The middle-aged age group shows the greatest level of interest.
• Many access the medications through private healthcare rather than the NHS.

Ultimately, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a permanent fix and lasting health benefits relies on ongoing behavioural changes.